SCHEMBL4978252

SCHEMBL4978252

COc1ccc(N(C(=O)OC(C)(C)C)c2nc3cc(N(C)c4ccnc(N(C)c5cccc(S(C)(=O)=O)c5)n4)ccc3n2C)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 8/20 0.40
CYP3A4 P08684 5/20 0.40
CYP2D6 P10635 5/20 0.40
CYP2C9 P11712 5/20 0.40
CYP2C19 P33261 5/20 0.40
KIT P10721 2/20 0.34
PDGFRA P16234 2/20 0.34
KDM4C Q9H3R0 1/20 0.33
MAPK14 Q16539 2/20 0.32
AURKA O14965 1/20 0.32
RIPK1 Q13546 1/20 0.32
MLKL Q8NB16 1/20 0.32
RIPK3 Q9Y572 1/20 0.32
KAT8 Q9H7Z6 1/20 0.32
DYRK1A Q13627 1/20 0.31
ABCB11 O95342 1/20 0.31
ALOX5AP P20292 1/20 0.31
GCG P01275 1/20 0.31
GCGR P47871 1/20 0.31
GIPR P48546 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4981198 0.94 KDR (0.36) KDRCYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL4978572 0.83 MAPK14 (0.37) KDRCYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL4978239 0.80 KDR (0.54) KDRCYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL4978683 0.79 KDR (0.46) KDRCYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL4981188 0.79 KDR (0.49) KDRCYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL4978772 0.79 KDR (0.37) KDRCYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL4975094 0.77 KDR (0.67) KDRCYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL4977012 0.77 KDR (0.46) KDRCYP3A4CYP2D6CYP2C9CYP2C19
Hydrochloric Acid SCHEMBL4975088 0.76 KDR (0.66) KDRCYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL6637801 0.76 KDR (0.38) KDRCYP3A4CYP2D6CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7338959-B2 Diamino-pyrimidines and their use as angiogenesis inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2008-03-04 US claimed
US-20050234083-A1 Diamino-pyrimidines and their use as angiogenesis inhibitors SMITHKLINE BEECHAM CORPORATION 2005-10-20 US claimed
EP-1487824-A1 DIAMINO-PYRIMIDINES AND THEIR USE AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2004-12-22 EP claimed
WO-2003074515-A1 DIAMINO-PYRIMIDINES AND THEIR USE AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2003-09-12 WO claimed
US-7338959-B2 Diamino-pyrimidines and their use as angiogenesis inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2008-03-04 US disclosed
US-20050234083-A1 Diamino-pyrimidines and their use as angiogenesis inhibitors SMITHKLINE BEECHAM CORPORATION 2005-10-20 US disclosed
EP-1487824-A1 DIAMINO-PYRIMIDINES AND THEIR USE AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2004-12-22 EP disclosed
WO-2003074515-A1 DIAMINO-PYRIMIDINES AND THEIR USE AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2003-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050234083-A1 Diamino-pyrimidines and their use as angiogenesis inhibitors TIE1, TEK, KDR KDR 3/4885CYP3A4 3874/4885CYP2D6 3399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.